CurrentRheuma Weekly: 2–8 November 2026

Featured

3 studies

Arthritis Rheumatol4 Nov
Effects of a Smartphone‐Enabled, Physician‐Supervised Treat‐to‐Target Model for Gout Management: A 12‐Month Randomized Controlled Trial
Randomized controlled trialGout & crystals
Osteoporos Int4 Nov
Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial
Randomized controlled trialOsteoporosis
Joint Bone Spine3 Nov
Factors associated with tocilizumab primary failure in the treatment of giant cell arteritis
Diagnostic or prognostic studyVasculitis & PMR

Also selected

6 studies

Lupus5 Nov
Patient selection for advanced B-cell-targeted therapy trials in systemic lupus erythematosus
Cohort studyLupus & APS
Semin Arthritis Rheum4 Nov
Biomarker trajectories and risk of relapse in giant cell arteritis: a multicenter study
Cohort studyVasculitis & PMR
Ann Rheum Dis4 Nov
Global burden and economic cost of musculoskeletal disorders in the working-age population, 1990-2023
Secondary analysisAcross diseases
Rheumatology (Oxford)4 Nov
Prevalence and clinical associations of age-related clonal hematopoiesis in systemic sclerosis
Case-control studySystemic sclerosis
Lupus Sci Med2 Nov
Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study
Secondary analysisLupus & APS
Lupus Sci Med2 Nov
Pulmonary function, functional capacity and physical activity in patients with SLE: a cross-sectional study
Cross-sectional studyLupus & APS

Explore all studies from this issue →